A Phase 2, multicenter, open-label, dose-escalation/dose-expansion study evaluating TYRA-300 in children ages 3 to 10 with achondroplasia with open growth plates.
Latest Information Update: 30 Oct 2024
At a glance
- Drugs TYRA-300 (Primary)
- Indications Achondroplasia
- Focus Therapeutic Use
- Acronyms BEACH301
- 30 Oct 2024 New trial record
- 28 Oct 2024 According to Tyra Biosciences media release, U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with this BEACH301 study and commence dosing in the first quarter of 2025."